Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe

H. FRASER ; N. K. MARTIN ; H. BRUMMER-KORVENKONTIO ; P. CARRIERI ; O. DALGARD ; J. DILLON ; D. GOLDBERG ; S. HUTCHINSON ; M. JAUFFRET-ROUSTIDE ; M. KABERG ; A. A. MATSER ; M. MATICIC ; H. MIDGARD ; V. MRAVCIK ; A. OVREHUS ; M. PRINS ; J. REIMER ; G. ROBAEYS ; B. SCHULTE ; D. K. VAN SANTEN ; R. ZIMMERMANN ; P. VICKERMAN ; M. HICKMAN | 2018
Dans Journal of Hepatology (Vol.68, n°3, March 2018) Article : Périodique

BACKGROUND & AIMS: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of current and scaled-up HCV treatment with and without scaling up opio[...]

Plus d'info

Ajouter à la sélection

Lien externe

Nouveauté

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs [Commentary]

J. GREBELY ; J. BRUNEAU ; J. V. LAZARUS ; O. DALGARD ; P. BRUGGMANN ; C. TRELOAR ; M. HICKMAN ; M. HELLARD ; T. ROBERTS ; L. CROOKS ; H. MIDGARD ; S. LARNEY ; L. DEGENHARDT ; H. ALHO ; J. BYRNE ; J. F. DILLON ; J. J. FELD ; G. FOSTER ; D. GOLDBERG ; A. R. LLOYD ; J. REIMER ; G. ROBAEYS ; M. TORRENS ; N. WRIGHT ; I. MAREMMANI ; B. L. NORTON ; A. H. LITWIN ; G. J. DORE ; International Network on Hepatitis in Substance Users | 2017
Dans International Journal of Drug Policy (Vol.47, September 2017) Article : Périodique

Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7.5 million people who have recently injected drugs (PWID). There is an additional large, but unquantified, burden among th[...]

Plus d'info

Ajouter à la sélection